{
    "clinical_study": {
        "@rank": "65645", 
        "acronym": "OPALE", 
        "arm_group": [
            {
                "arm_group_label": "1:  early conversion from Prograf\u00ae to Advagraf\u00ae", 
                "description": "patients converted during the first 6 months post-transplantation"
            }, 
            {
                "arm_group_label": "2:  late conversion from Prograf\u00ae to Advagraf\u00ae", 
                "description": "patients converted between 6 and 12 months post-transplantation"
            }
        ], 
        "brief_summary": {
            "textblock": "Assessment in a real situation of the conversion conditions, the efficacy and the safety of\n      the treatment with tacrolimus in renal transplant patients converted from the tacrolimus\n      twice per day form (Prograf\u00ae) to the tacrolimus once per day form (Advagraf\u00ae) with follow-up\n      at one year.\n\n      Analysis of two groups of patients: patients converted from Prograf\u00ae to Advagraf\u00ae early\n      (during the first 6 months post-transplantation) or late (between 6 and 12 months\n      post-transplantation)."
        }, 
        "brief_title": "A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf\u00ae) to the Once Per Day Form (Advagraf\u00ae)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Transplantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Renal transplant patient for less than one year\n\n          -  Patient where the conversion from Prograf\u00ae to Advagraf\u00ae has been decided by the\n             doctor\n\n        Exclusion Criteria:\n\n          -  Patient participating in an interventional clinical trial at the time of inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Renal transplant patients"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147938", 
            "org_study_id": "FR-ADV-NI-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1:  early conversion from Prograf\u00ae to Advagraf\u00ae", 
                    "2:  late conversion from Prograf\u00ae to Advagraf\u00ae"
                ], 
                "description": "oral", 
                "intervention_name": "Prograf\u00ae", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK506,", 
                    "tacrolimus"
                ]
            }, 
            {
                "arm_group_label": [
                    "1:  early conversion from Prograf\u00ae to Advagraf\u00ae", 
                    "2:  late conversion from Prograf\u00ae to Advagraf\u00ae"
                ], 
                "description": "oral", 
                "intervention_name": "Advagraf\u00ae", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK506E,", 
                    "tacrolimus"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Prograf", 
            "Advagraf", 
            "Tacrolimus", 
            "France", 
            "Observational"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "number_of_groups": "2", 
        "official_title": "French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf\u00ae) to the Once Per Day Form (Advagraf\u00ae)", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Medical Dept Clinical Operations Dept", 
            "phone": "+31 (0)71 545 5050"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma S.A.S.", 
            "last_name": "Medical and Scientific Affairs Manager, Transplantation", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of patients with a tacrolimus dose conversion ratio of 1mg / 1mg and percentage of patients with a ratio \u2260 1mg / 1mg", 
                "measure": "Tacrolimus daily dose conversion ratio (mg Prograf\u00ae / mg Advagraf\u00ae)", 
                "safety_issue": "No", 
                "time_frame": "At baseline (i.e. time of conversion)"
            }, 
            {
                "description": "number of days between the date of conversion and the date of first assay of C0 after conversion", 
                "measure": "Time to measurement of the first trough tacrolimus blood concentration (C0) after conversion", 
                "safety_issue": "No", 
                "time_frame": "From baseline (conversion) to first determination of C0 assessed up to one year"
            }, 
            {
                "description": "percentage of patients with additional visit(s) and percentage of patients without additional visit", 
                "measure": "Number of additional visits that the doctor considers to be due to the conversion (if applicable)", 
                "safety_issue": "No", 
                "time_frame": "At 6 months and at 1 year follow-up visit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "number of capsules, poor treatment compliance, requested by patient, safety, centre practice, other", 
                "measure": "Reasons for the conversion", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "sociodemographic data, transplantation history, comorbidities, post-transplantation complications, risk factors and concomitant treatments (Immunosuppressive protocols (IS) and others) at the time of conversion and changes, if applicable, at 6 months and 1 year post-conversion", 
                "measure": "Profile of the patients in both groups", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "measure": "Time to reach steady state", 
                "safety_issue": "No", 
                "time_frame": "Time from baseline (conversion) to steady state C0 assessed up to one year"
            }, 
            {
                "description": "calculation of the tacrolimus daily dose ratio once the steady state is reached: mg Prograf\u00ae at conversion / mg Advagraf\u00ae once the steady state is reached. Percentage of patients with a ratio of 1mg / 1mg and percentage of patients with a ratio \u2260 1mg / 1mg.", 
                "measure": "Dose ratio at steady state", 
                "safety_issue": "No", 
                "time_frame": "At baseline (conversion) and up to 6 months post-baseline"
            }, 
            {
                "measure": "The intra-patient variability (IPV) of tacrolimus", 
                "safety_issue": "No", 
                "time_frame": "At baseline and up to 6 months post-baseline"
            }, 
            {
                "description": "Values and dates for blood and urine renal parameters, blood glucose", 
                "measure": "Latest available laboratory data with Prograf\u00ae before conversion and with Advagraf\u00ae", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 6 months and 1 year follow-up visit"
            }, 
            {
                "description": "Compliance with the treatment at conversion (taking Prograf\u00ae) and at 1 year post-conversion (taking Advagraf\u00ae) only in group 2 (late conversion) will be assessed using the Morisky questionnaire, from which a score will be calculated", 
                "measure": "Compliance with the treatment at conversion and at 1 year post-conversion", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 1 year follow-up visit"
            }, 
            {
                "description": "The quality of life of the patient at conversion (taking Prograf\u00ae) and at 1 year post-conversion (taking Advagraf\u00ae) only in group 2 (late conversion) will be assessed using the EQ5D-5L questionnaire", 
                "measure": "The quality of life of the patient at conversion and at 1 year post-conversion", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 1 year follow-up visit"
            }, 
            {
                "measure": "Incidence of biopsy proven acute rejections (BPAR) and survival of the graft and of the patient", 
                "safety_issue": "No", 
                "time_frame": "At 1 year follow-up visit"
            }, 
            {
                "measure": "Occurrence of adverse effects", 
                "safety_issue": "No", 
                "time_frame": "From baseline until 1 year follow-up visit after baseline (conversion)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma S.A.S.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}